Parkinson’s Disease Therapeutic Market, 2018-2026 by Segmentation: Based on Product, Application and Region
Parkinson's
disease (PD) is a chronic disorder characterized by the
malfunctioning and death of vital nerve cells in the brain, and can
be characterized by tremor, dementia, and depression. Parkinson's
disease progression leads to uncontrolled body movement of the
patient. There is no cure presently for Parkinson's disease only
treatments options such as medication and surgery to manage the
symptoms are available. Parkinson's disease mainly affects people
over 50 and the risk increases with increasing age. Parkinson's
disease treatment is used to control symptoms such as uncontrolled
movement, shakiness of hands, and some others. The therapeutic
approaches like levodopa in combination with carbidopa is considered
as an effective treatment over symptoms of Parkinson's disease. The
surgical treatment option is available but it is only effective for
patients who are previously responded to levodopa therapy. The
research and development in the field of Parkinson's disease
therapeutic will help in the treatment of Parkinson's disease.
Increase in
prevalence of Parkinson's disease across the world is driving the
Parkinson’s disease therapeutics market
According to
Parkinson's disease foundation, more than 10 million people globally
are living with Parkinson's disease and 60,000 Americans are
diagnosed with Parkinson's disease each year. The rising prevalence
of Parkinson's disease across the world is one of the major factor
which is driving the Parkinson's disease therapeutic market. Rising
male patients, is also the major factor owing to Parkinson's disease
therapeutic market, because as mentioned in the data of Parkinson's
disease foundation, chances of getting Parkinson's disease are one
and half times more in men than women. The increase in number of
geriatric population and technological advancements such as
combination therapies for prolong action of continuous dopaminergic
stimulation drugs, gene therapy, neural transplantation are some
other causes which are likely to drive the Parkinson's disease
therapeutic market. However some restraints like expiry of patents
for several drugs such as Stalevo, Azilect, Rytary, Comtan etc. can
cause the cessation of Parkinson's disease therapeutic market.
The advancements
in medical devices segment for Parkinson's disease treatment is
expected to boost the growth in Parkinson's disease therapeutic
market
Global Parkinson's
disease therapeutic market is segmented on the basis of treatment
type, end user and geographical regions
On the basis of
treatment type:
Medical Devices
Deep Brain
Stimulation (DBS) Devices
Carbidopa/Levodopa Enteral Suspension (Duopa) delivery devices
Drug Class
Dopamine
precursors
COMT
Inhibitors
MAO
Inhibitors
Peripheral
Decarboxylase Inhibitors
Others
On the basis of end
user:
Clinics
Hospitals
Homecare
Settings
Request For
Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/494
New advancements
in the treatment of Parkinson's disease has helped to boost the
growth in North America for Parkinson's disease therapeutic market.
Regional
segmentation of Parkinson's disease therapeutic market according to
coherent market Insights comprises of North America, Latin America,
Europe, Asia pacific, Middle East, and Africa. High prevalence of
Parkinson's disease and good reimbursement policies are some of
factors which allows the North America region to dominate in the
Parkinson's disease market. For instance, over 40 medicines are
developed for the treatment of parkinsons disease and many have
gained the fast track designation from U.S. Food and Drug
Administration (FDA) in North America. North America is expected to
hold the largest share in the Parkinson's disease market because of
increase in investments in research and development for Parkinson's
disease.
New product
development is the key strategy adopted by major industry player in
Parkinson's disease therapeutics market
Key players in
the Parkinson's disease therapeutics market globally are Salix
Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Novartis AG,
GlaxoSmithKline Plc., Mylan N.V., Orion Corporation, Boehringer
Ingelheim, UCB, and Impax Labs. Many of the key players involved in
the anti-Parkinson's disease medication and some of the
biopharmaceuticals research companies in the U.S. are currently in
the development of new medicines for treatment of Parkinson's
disease. The industry players such as Novartis AG, Pfizer, Ceregene,
and Biogen are expected to launch new drugs for Parkinson's disease
treatment in the future.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment